The Experts below are selected from a list of 3378 Experts worldwide ranked by ideXlab platform

K G Garaeva - One of the best experts on this subject based on the ideXlab platform.

  • effect of calcium channel blockers long term use on Blood Level of luteinizing hormone and Estradiol in rats
    Kazanskiy meditsinskiy zhurnal, 2014
    Co-Authors: A U Kazimova, K G Garaeva
    Abstract:

    Aim. To define the effect of calcium channel blockers long-term use on Blood Level of luteinizing hormone and Estradiol in female rats. Methods. 82 mature female outbreed rats were distributed to seven groups. The rats of the first (control) group were administered 0.2 ml of 0.9% saline intraperitoneally for 21 day. Instead of saline, 5 and 25 mg/kg of verapamil were used in rats of the second and third groups, 5 and 10 mg/kg of nifedipine - in rats of the 4th and 5th groups, 5 and 20 mg/kg of diltiazem - in rats of the 6th and 7th groups accordingly. Blood Levels of luteinizing hormone and Estradiol were determined by ELISA after animals were withdrawn from the study. Results. In rats treated with calcium channel blockers, a dose-dependent decrease of luteinizing hormone and Estradiol Blood Levels were observed. High doses of verapamil (group 3) decreased the Level of luteinizing hormones and Estradiol by 50% compared to control group, high doses of diltiazem (group 7) - by 50%. Only minor changes were observed in rats who were administered nifedipine, even in high doses. Conclusion. Observed decrease of Blood Estradiol Level indicate the influence of calcium channel blockers directly on ovarian function; decrease of Blood luteinizing hormone Level might by secondary due to positive feedback between the Estradiol and luteinizing hormone secretion and reflect decreased Estradiol Blood Level.

Kulkarni J - One of the best experts on this subject based on the ideXlab platform.

  • Serum Estradiol as a Blood-based biomarker predicting hormonal treatment outcomes in women with schizophrenia
    'Elsevier BV', 2021
    Co-Authors: Thomas N, Gurvich C, Hudaib A-r, Gavrilidis E, Ra ,de Castella, Thomas Ehx, Kulkarni J
    Abstract:

    Patients diagnosed with schizophrenia display substantial heterogeneity in terms of their clinical presentations, and treatment response. Accumulating research suggests that such high diversity may reflect distinct biological subtypes with differentially affected underlying neurobiology. Novel treatments, including sex hormone Estradiol treatments, provide alternative efficacious treatment avenues but also should be studied within the context of potential heterogeneity. This repeated-measures study characterised the association between hormone Levels (estrogen, progesterone, testosterone, prolactin, FSH, LH, DHEA) and symptom treatment outcomes (defined by The Positive and Negative Syndrome Scale (PANSS)) across a 56-day study of 200 ug adjunctive Estradiol treatment in women with schizophrenia. Group-based trajectory models was used to account for potential heterogeneity (subgroups). Receiver operating characteristic (ROC) curves were evaluated to define the predictive value of endogenous Estradiol Levels as a treatment-response biomarker of Estradiol treatment. The results generated two subgroups; a treatment-responder group who demonstrated decreasing PANSS scores across time, and a treatment non-responder group, demonstrating stable PANSS scores across time. The treatment-responder subgroup was significantly negatively predicted by Estradiol Blood Level (b= 2.34, SE= 1.17, p = 0.047), while FSH Blood Level was positively associated with the treatment non-responders (b= 7.14, SE= 2.54, p = 0.008). ROC for day 28, 56 time points yielded area under the curve of 0.52 and 0.55, respectively. Harrell’s C-statistic = 0.59. This is the first study to identify endocrine markers in Blood serum predicting response to Estradiol treatment in female schizophrenia patients, highlighting the existence of heterogeneity of response, indicative of molecular subtypes. Characterising the differential underlying biology of the subgroups may lead to better targeted, specific treatments in the future.(ClinicalTrials.gov Identifier: NCT00357006). https://www.clinicaltrials. gov/ct2/show/NCT00357006

A U Kazimova - One of the best experts on this subject based on the ideXlab platform.

  • effect of calcium channel blockers long term use on Blood Level of luteinizing hormone and Estradiol in rats
    Kazanskiy meditsinskiy zhurnal, 2014
    Co-Authors: A U Kazimova, K G Garaeva
    Abstract:

    Aim. To define the effect of calcium channel blockers long-term use on Blood Level of luteinizing hormone and Estradiol in female rats. Methods. 82 mature female outbreed rats were distributed to seven groups. The rats of the first (control) group were administered 0.2 ml of 0.9% saline intraperitoneally for 21 day. Instead of saline, 5 and 25 mg/kg of verapamil were used in rats of the second and third groups, 5 and 10 mg/kg of nifedipine - in rats of the 4th and 5th groups, 5 and 20 mg/kg of diltiazem - in rats of the 6th and 7th groups accordingly. Blood Levels of luteinizing hormone and Estradiol were determined by ELISA after animals were withdrawn from the study. Results. In rats treated with calcium channel blockers, a dose-dependent decrease of luteinizing hormone and Estradiol Blood Levels were observed. High doses of verapamil (group 3) decreased the Level of luteinizing hormones and Estradiol by 50% compared to control group, high doses of diltiazem (group 7) - by 50%. Only minor changes were observed in rats who were administered nifedipine, even in high doses. Conclusion. Observed decrease of Blood Estradiol Level indicate the influence of calcium channel blockers directly on ovarian function; decrease of Blood luteinizing hormone Level might by secondary due to positive feedback between the Estradiol and luteinizing hormone secretion and reflect decreased Estradiol Blood Level.

Thomas N - One of the best experts on this subject based on the ideXlab platform.

  • Serum Estradiol as a Blood-based biomarker predicting hormonal treatment outcomes in women with schizophrenia
    'Elsevier BV', 2021
    Co-Authors: Thomas N, Gurvich C, Hudaib A-r, Gavrilidis E, Ra ,de Castella, Thomas Ehx, Kulkarni J
    Abstract:

    Patients diagnosed with schizophrenia display substantial heterogeneity in terms of their clinical presentations, and treatment response. Accumulating research suggests that such high diversity may reflect distinct biological subtypes with differentially affected underlying neurobiology. Novel treatments, including sex hormone Estradiol treatments, provide alternative efficacious treatment avenues but also should be studied within the context of potential heterogeneity. This repeated-measures study characterised the association between hormone Levels (estrogen, progesterone, testosterone, prolactin, FSH, LH, DHEA) and symptom treatment outcomes (defined by The Positive and Negative Syndrome Scale (PANSS)) across a 56-day study of 200 ug adjunctive Estradiol treatment in women with schizophrenia. Group-based trajectory models was used to account for potential heterogeneity (subgroups). Receiver operating characteristic (ROC) curves were evaluated to define the predictive value of endogenous Estradiol Levels as a treatment-response biomarker of Estradiol treatment. The results generated two subgroups; a treatment-responder group who demonstrated decreasing PANSS scores across time, and a treatment non-responder group, demonstrating stable PANSS scores across time. The treatment-responder subgroup was significantly negatively predicted by Estradiol Blood Level (b= 2.34, SE= 1.17, p = 0.047), while FSH Blood Level was positively associated with the treatment non-responders (b= 7.14, SE= 2.54, p = 0.008). ROC for day 28, 56 time points yielded area under the curve of 0.52 and 0.55, respectively. Harrell’s C-statistic = 0.59. This is the first study to identify endocrine markers in Blood serum predicting response to Estradiol treatment in female schizophrenia patients, highlighting the existence of heterogeneity of response, indicative of molecular subtypes. Characterising the differential underlying biology of the subgroups may lead to better targeted, specific treatments in the future.(ClinicalTrials.gov Identifier: NCT00357006). https://www.clinicaltrials. gov/ct2/show/NCT00357006

Gurvich C - One of the best experts on this subject based on the ideXlab platform.

  • Serum Estradiol as a Blood-based biomarker predicting hormonal treatment outcomes in women with schizophrenia
    'Elsevier BV', 2021
    Co-Authors: Thomas N, Gurvich C, Hudaib A-r, Gavrilidis E, Ra ,de Castella, Thomas Ehx, Kulkarni J
    Abstract:

    Patients diagnosed with schizophrenia display substantial heterogeneity in terms of their clinical presentations, and treatment response. Accumulating research suggests that such high diversity may reflect distinct biological subtypes with differentially affected underlying neurobiology. Novel treatments, including sex hormone Estradiol treatments, provide alternative efficacious treatment avenues but also should be studied within the context of potential heterogeneity. This repeated-measures study characterised the association between hormone Levels (estrogen, progesterone, testosterone, prolactin, FSH, LH, DHEA) and symptom treatment outcomes (defined by The Positive and Negative Syndrome Scale (PANSS)) across a 56-day study of 200 ug adjunctive Estradiol treatment in women with schizophrenia. Group-based trajectory models was used to account for potential heterogeneity (subgroups). Receiver operating characteristic (ROC) curves were evaluated to define the predictive value of endogenous Estradiol Levels as a treatment-response biomarker of Estradiol treatment. The results generated two subgroups; a treatment-responder group who demonstrated decreasing PANSS scores across time, and a treatment non-responder group, demonstrating stable PANSS scores across time. The treatment-responder subgroup was significantly negatively predicted by Estradiol Blood Level (b= 2.34, SE= 1.17, p = 0.047), while FSH Blood Level was positively associated with the treatment non-responders (b= 7.14, SE= 2.54, p = 0.008). ROC for day 28, 56 time points yielded area under the curve of 0.52 and 0.55, respectively. Harrell’s C-statistic = 0.59. This is the first study to identify endocrine markers in Blood serum predicting response to Estradiol treatment in female schizophrenia patients, highlighting the existence of heterogeneity of response, indicative of molecular subtypes. Characterising the differential underlying biology of the subgroups may lead to better targeted, specific treatments in the future.(ClinicalTrials.gov Identifier: NCT00357006). https://www.clinicaltrials. gov/ct2/show/NCT00357006